Table 2 Primary, secondary, and other related outcomes, according to ADRB2 Arg16Gly (A > G)
Outcome | AA genotype | AG genotype | GG genotype | HRa (95% CI) or ORb | P value |
|---|---|---|---|---|---|
(N = 919) | (N = 1112) | (N = 355) | AG/GG vs. AA | ||
Primary composite outcome—no. (%) | |||||
Death from cardiovascular causes or heart transplantation | 129 (14.0) | 209 (18.8) | 81 (22.8) | 1.49 (1.21–1.83) | <0.001 |
Death from cardiovascular causes | 124 (13.5) | 193 (17.4) | 74 (20.8) | 1.44 (1.16–1.79) | 0.001 |
Secondary outcomes—no. (%) | |||||
Death from any cause | 138 (15.0) | 226 (20.3) | 84 (23.7) | 1.50 (1.22–1.83) | <0.001 |
First hospitalization for cardiovascular causes | 243 (26.4) | 355 (31.9) | 110 (31.0) | 1.26 (1.08–1.48) | 0.003 |
First hospitalization for any cause | 317 (34.1) | 482 (43.3) | 130 (36.6) | 1.30 (1.13–1.49) | <0.001 |
Recurrence of heart failure | 228 (24.8) | 304 (27.3) | 99 (27.9) | 1.15 (0.98–1.36) | 0.086 |
Other related outcomes—no. (%) | |||||
New onset of stroke | 12 (1.3) | 23 (2.1) | 5 (1.4) | 1.41 (0.72–2.78) | 0.320 |
Improvement in NYHA class | 505 (55.0) | 557 (50.1) | 170 (47.9) | 1.22 (1.03–1.45) | 0.021 |
